Immortal Dragons Deploys $40M Longevity Fund Targeting Early-Stage Life Extension Technologies

Immortal Dragons, a Singapore-based longevity-focused investment fund, is deploying $40 million in assets under management across early-stage companies working on life extension and age-related disease. Founded by Boyang Wang, the fund operates as a single-LP vehicle, allowing it to invest its own capital into high-risk, long-horizon projects. It raised the capital in July 2025

The fund targets multiple areas within the longevity ecosystem, including gene therapy, 3D bioprinting, and biological regeneration. Its investment strategy spans technologies such as organ replacement, cryopreservation, and therapies designed to address the underlying drivers of aging. In addition, Immortal Dragons is backing infrastructure initiatives aimed at accelerating clinical trials and enabling new regulatory environments for longevity research.

To date, the fund has invested in more than 15 startups across these categories. Its model prioritises scientific impact over near-term financial returns, with a focus on supporting projects that may be overlooked by traditional venture capital due to their risk profile or longer timelines.

Beyond direct investment, Immortal Dragons is also involved in advocacy and ecosystem development. Activities include funding research initiatives, supporting industry events, and producing educational content to increase awareness of longevity science. The fund is positioning itself as both a capital provider and an enabler of broader infrastructure for the longevity sector.